Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4Observational 1Expanded_access 1

Sponsor

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

tremelimumab 1durvalumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Advanced Malignancy × Clear all
NCT07123129 2026-01-30

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Recruiting
200 enrolled

Advanced Malignancy

NCT03875157 2023-02-27

Study of IBI318 in Participants With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
103 enrolled

Advanced Malignancy

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
93 enrolled

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡